170 related articles for article (PubMed ID: 30394384)
1. An In Vivo Method for Evaluating the Gut-Blood Barrier and Liver Metabolism of Microbiota Products.
Jaworska K; Huc T; Gawrys M; Onyszkiewicz M; Samborowska E; Ufnal M
J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394384
[TBL] [Abstract][Full Text] [Related]
2. The gut-blood barrier permeability - A new marker in cardiovascular and metabolic diseases?
Ufnal M; Pham K
Med Hypotheses; 2017 Jan; 98():35-37. PubMed ID: 28012600
[TBL] [Abstract][Full Text] [Related]
3. Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite.
Jaworska K; Huc T; Samborowska E; Dobrowolski L; Bielinska K; Gawlak M; Ufnal M
PLoS One; 2017; 12(12):e0189310. PubMed ID: 29236735
[TBL] [Abstract][Full Text] [Related]
4. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Arab JP; Martin-Mateos RM; Shah VH
Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
[TBL] [Abstract][Full Text] [Related]
5. Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease.
Compare D; Coccoli P; Rocco A; Nardone OM; De Maria S; Cartenì M; Nardone G
Nutr Metab Cardiovasc Dis; 2012 Jun; 22(6):471-6. PubMed ID: 22546554
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota-related complications in cirrhosis.
Gómez-Hurtado I; Such J; Sanz Y; Francés R
World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
[TBL] [Abstract][Full Text] [Related]
7. Suppression of intestinal microbiota-dependent production of pro-atherogenic trimethylamine N-oxide by shifting L-carnitine microbial degradation.
Kuka J; Liepinsh E; Makrecka-Kuka M; Liepins J; Cirule H; Gustina D; Loza E; Zharkova-Malkova O; Grinberga S; Pugovics O; Dambrova M
Life Sci; 2014 Nov; 117(2):84-92. PubMed ID: 25301199
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory bowel disease is associated with increased gut-to-blood penetration of short-chain fatty acids: A new, non-invasive marker of a functional intestinal lesion.
Jaworska K; Konop M; Bielinska K; Hutsch T; Dziekiewicz M; Banaszkiewicz A; Ufnal M
Exp Physiol; 2019 Aug; 104(8):1226-1236. PubMed ID: 31243807
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota and host metabolism in liver cirrhosis.
Usami M; Miyoshi M; Yamashita H
World J Gastroenterol; 2015 Nov; 21(41):11597-608. PubMed ID: 26556989
[TBL] [Abstract][Full Text] [Related]
10. Role of the intestinal microbiome in liver disease.
Henao-Mejia J; Elinav E; Thaiss CA; Licona-Limon P; Flavell RA
J Autoimmun; 2013 Oct; 46():66-73. PubMed ID: 24075647
[TBL] [Abstract][Full Text] [Related]
11. [The role of gut microbiota in chronic liver diseases, and treatment possibilities].
Hagymási K; Bacsárdi A; Egresi A; Berta E; Tulassay Z; Lengyel G
Orv Hetil; 2018 Sep; 159(36):1465-1474. PubMed ID: 30175608
[TBL] [Abstract][Full Text] [Related]
12. Alterations of intestinal barrier and microbiota in chronic kidney disease.
Sabatino A; Regolisti G; Brusasco I; Cabassi A; Morabito S; Fiaccadori E
Nephrol Dial Transplant; 2015 Jun; 30(6):924-33. PubMed ID: 25190600
[TBL] [Abstract][Full Text] [Related]
13. Gut microbiota and liver diseases.
Minemura M; Shimizu Y
World J Gastroenterol; 2015 Feb; 21(6):1691-702. PubMed ID: 25684933
[TBL] [Abstract][Full Text] [Related]
14. Intestinal environmental disorders associate with the tissue damages induced by perfluorooctane sulfonate exposure.
Wang G; Sun S; Wu X; Yang S; Wu Y; Zhao J; Zhang H; Chen W
Ecotoxicol Environ Saf; 2020 Jul; 197():110590. PubMed ID: 32283409
[TBL] [Abstract][Full Text] [Related]
15. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
Ji Y; Yin Y; Li Z; Zhang W
Nutrients; 2019 Jul; 11(8):. PubMed ID: 31349604
[TBL] [Abstract][Full Text] [Related]
16. A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature.
Giuffrè M; Campigotto M; Campisciano G; Comar M; Crocè LS
Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G889-G906. PubMed ID: 32146836
[TBL] [Abstract][Full Text] [Related]
17. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target.
Miele L; Marrone G; Lauritano C; Cefalo C; Gasbarrini A; Day C; Grieco A
Curr Pharm Des; 2013; 19(29):5314-24. PubMed ID: 23432669
[TBL] [Abstract][Full Text] [Related]
18. Outside the liver box: The gut microbiota as pivotal modulator of liver diseases.
Wahlström A
Biochim Biophys Acta Mol Basis Dis; 2019 May; 1865(5):912-919. PubMed ID: 31007175
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
Li DY; Yang M; Edwards S; Ye SQ
JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal Simulation Model TWIN-SHIME Shows Differences between Human Urolithin-Metabotypes in Gut Microbiota Composition, Pomegranate Polyphenol Metabolism, and Transport along the Intestinal Tract.
García-Villalba R; Vissenaekens H; Pitart J; Romo-Vaquero M; Espín JC; Grootaert C; Selma MV; Raes K; Smagghe G; Possemiers S; Van Camp J; Tomas-Barberan FA
J Agric Food Chem; 2017 Jul; 65(27):5480-5493. PubMed ID: 28616977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
